SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gene therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (79)6/23/1999 5:45:00 AM
From: SnowShredder   of 319
 
Peter, Thanks for the link, the author Isner is the one who did the presentation...very interesting stuff.

Interestingly, NXTR was working on anti-VEGF in macular degeneration: "NX1838 binds to VEGF[165] with low picomolar affinity, and potently inhibits VEGF-mediated effects both in vitro and in vivo," he said.

NXTR...interesting...next thing you know they'll be using it for cancer therapy, too ;) Best of Luck, Where'd He Go?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News